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Clifton O. Bingham III1*, Kevin L. Winthrop2, Lili Yang3, Chin Lee3 and Wendy J. Komocsar3Vaccination remains an important strategy in the care of
autoimmune disease patients. Patients with rheumatoid
arthritis (RA) are at increased risk for infection due to
disease-induced immune dysregulation; however, vaccine
efficacy can be impaired by concomitant immunomodula-
tors [1, 2]. Tabalumab is a human monoclonal antibody
that neutralizes both soluble and membrane-bound B-cell
activating factor (BAFF) [3] and was previously investi-
gated for the treatment of RA and systemic lupus erythe-
matosus. While tabalumab development was discontinued
following insufficient efficacy observed in phase 3 RA/sys-
temic lupus erythematosus studies, other BAFF pathway
drugs are approved for (belimumab) or being investigated
in (atacicept, briobacept) other autoimmune indications,
and BAFF bi-specific molecules are in development. Given
the importance of immunizations to decrease infection
risk in autoimmune diseases and the potential for BAFF
antagonists to affect responses, we wished to share data
from a tabalumab vaccine substudy in RA.
Patients with RA on background methotrexate (MTX)
therapy received either a 240 mg loading dose followed by
120 mg of tabalumab monthly (120/Q4W), 180 mg loading
dose followed by 90 mg of tabalumab every bi-weekly (90/
Q2W), or placebo, and were vaccinated with tetanus, diph-
theria, acellular pertussis vaccine (TDaP) and 23-valent
pneumococcal polysaccharide (PPSV-23) 24 weeks after drug
start. A study flow chart shows this in more detail
(Additional file 1). Detailed patient demographic informa-
tion and study methods are included as Additional file 2* Correspondence: cbingha2@jhmi.edu
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was approved by the local institutional review boards in ac-
cordance with the Declaration of Helsinki and applicable
laws, and all patients provided voluntary written informed
consent.Findings
Sixty-nine patients completed the vaccine substudy; the
substudy was part of a larger 52-week study [4]. Ex-
pected reductions in total and naïve B cells and increases
in memory B cells were observed (Fig. 1). Total immu-
noglobulins (Ig) were significantly reduced compared
with placebo (Additional file 3). Immunization response
data are presented in Table 1. More patients achieved an
adequate tetanus IgG response (fourfold or greater in-
crease from baseline) in the 120/Q4W group compared
with 90/Q2W or placebo, and the 90/Q2W group was not
significantly different from placebo. Further, tabalumab-
treated patients had similar responses as placebo in the
development of total pneumococcal IgG (twofold or
greater increase from baseline). Pre-existing immunity to
measles and mumps was also not affected by tabalumab
(Supplemental Table 2 in Additional file 2).
Overall this study shows that treatment with tabalu-
mab for 24 weeks did not significantly affect the re-
sponse to protein or polysaccharide vaccines in RA
patients despite expected reductions in B cells and total
immunoglobulins.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 B-cell populations in tabalumab-treated patients versus placebo-treated patients. The percentage change from baseline values in absolute
counts of total CD19+ B cells (a), CD3-CD20+ B cells (b), CD19 + IgD-CD27- immature B cells (c), CD19 + IgD + CD27- mature naïve B cells (d),
CD19 + IgD-CD27+ switched memory B cells (e), and CD19 + IgD + CD27+ unswitched memory B cells (f) comparing tabalumab-treated (120/Q4W
and 90/Q2W) patients and placebo-treated patients. P values represent significance in the change from baseline values between tabalumab-treated
groups and placebo at week 52 mLOCF (modified last observation carried forward)
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Table 1 Week 28 (4 weeks post-vaccination) tetanus and pneumococcal antibody immunization responses following 24 weeks of
tabalumab treatment
120/Q4W 90/Q2W Placebo P value versus placebo
120/Q4W 90/Q2W
Tetanus IgG antibody response n = 21a n = 30a n = 17a
Number of patients with ≥4-fold titer increase
where baseline titers ≥0.1 IU/mlb (%)
17 (81.0) 13 (43.3) 10 (58.8) 0.167 0.371
Number of patients with ≥2-fold titer increase
where baseline titers ≥0.1 IU/mlb (%)
19 (90.5) 19 (63.3) 10 (58.8) 0.051 0.766
GMT pre-vaccination baseline (95 % CI) 0.301 (0.182, 0.498) 0.491 (0.280, 0.861) 0.341 (0.163, 0.711)
GMT 4 weeks post-vaccination (95 % CI) 3.495 (1.469, 8.315) 2.216 (1.151, 4.267) 1.963 (0.674, 5.713) 0.263c 0.423c
Total pneumococcal IgG antibody response n = 21a n = 31a n = 17a
Number of patients with ≥2-fold titer increase
where baseline titers ≥4 mg/Lb (%)
15 (71.4) 23 (74.2) 13 (76.5) >0.999 >0.999
GMT pre-vaccination baseline (95 % CI) 61.78 (46.30, 82.42) 63.77 (50.06, 81.23) 52.53 (36.33, 75.95)
GMT post-vaccination (95 % CI) 235.62 (150.97, 367.72) 220.81 (147.19, 331.26) 213.04 (121.83, 372.52) 0.835c 0.563c
CI confidence interval, GMT geometric mean titer, Ig immunoglobulin, 120/Q4W 120 mg tabalumab every 4 weeks, 90/Q2W 90 mg tabalumab every 2 weeks
aThe n values represent the number of patients immunized with vaccine and a baseline and a 28 week antibody titer
bOr a titer of ≥0.2 IU/ml for patients with baseline titers <0.1 IU/ml (tetanus) or ≥6 mg/L for patients with baseline titers <4 mg/L (pneumococcus)
cP value based on change from baseline log transformed data; rather than providing log transformed titers, we present geometric mean titers as this is the
standard way to report these data
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Additional file 1: Supplemental Fig. 1. Flowchart for study design.
Figure showing study design, treatment groups, and timing of
immunizations and assessments. (TIF 235 kb)
Additional file 2: Methods, Supplemental Table 1, Supplemental
Table 2, References. Methods: Description of patient population, study
design, endpoints, and analyses. Supplemental Table 1. Baseline
demographics and disease characteristics of study groups. Supplemental
Table 2. Geometric mean titers of measles and mumps IgG. References
for Methods. (DOCX 30 kb)
Additional file 3: Supplemental Fig. 2. Immunoglobulin levels in
tabalumab-treated patients versus placebo-treated patients. (TIF 111 kb)
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